Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELLVACCINE TRIAL

Next Previous
X
Search
Trial Profile

A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELLVACCINE TRIAL

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 12 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-2019 vaccine-ImmunityBio (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Acronyms The TCELLVACCINE TRIAL
  • Sponsors ImmunityBio

    • Most Recent Events

    • 05 Jun 2024 Status changed from completed to discontinued because as per the quality control review the primary outcome measure does not appear to include sufficient information and the arms/groups appear inconsistent with information in other parts of the record. Due to premature termination, no participant were enrolled in the Phase 3 part of the study.
    • 30 Aug 2023 Status changed to completed.
    • 10 Dec 2020 Status changed from planning to recruiting, according to an ImmunityBio media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top